Martek Biosciences Corporation has announced that Mead Johnson Nutritionals has received clearance from the US Food and Drug Administration (FDA) to introduce Enfamil Premature LIPIL, a pre-term version of Enfamil LIPIL.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
LIPIL contains a blend of Martek’s docosahexaenoic acid (DHA) and arachidonic acid (ARA), two nutrients that are described as the building blocks of a baby’s brain and eyes. The levels of DHA and ARA used in LIPIL are consistent with the levels recommended by the World Health Organisation and other international organisations and consistent with the levels used in numerous studies that have demonstrated positive effects on infant development.
Mead received FDA clearance and launched Enfamil LIPIL for term infants in the US in February 2002.
